Emerging Medical Treatment for Hypertrophic Cardiomyopathy.
Alessia ArgiròMattia ZampieriMartina BerteottiAlberto MarchiLuigi TassettiChiara ZocchiLuisa IannoneBeatrice BacchiFrancesco CappelliPierluigi StefànoNiccolò MarchionniIacopo OlivottoPublished in: Journal of clinical medicine (2021)
Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms in patients with HCM is left ventricular outflow tract (LVOT) obstruction. This phenomenon is multifactorial, determined both by anatomical and functional abnormalities: myocardial hypercontractility is believed to represent one of its major determinants. The anatomical anomalies are targeted by surgical interventions, whereas attenuating hypercontractility is the objective of old and new drugs including the novel class of allosteric myosin inhibitors. This review summarizes the current treatment modalities and discusses the emerging therapeutical opportunities focusing on the recently developed cardiac myosin ATPase inhibitors Mavacamten and CK-274. Novel surgical and interventional approaches are also discussed.
Keyphrases
- hypertrophic cardiomyopathy
- left ventricular
- cardiac resynchronization therapy
- acute myocardial infarction
- heart failure
- left atrial
- aortic stenosis
- mitral valve
- healthcare
- small molecule
- physical activity
- binding protein
- combination therapy
- coronary artery disease
- acute coronary syndrome
- sleep quality
- replacement therapy
- endoplasmic reticulum